OTCMKTS:NICXF Nicox (NICXF) Stock Price, News & Analysis $0.30 0.00 (0.00%) As of 10/1/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and Trends About Nicox Stock (OTCMKTS:NICXF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nicox alerts:Sign Up Key Stats Today's Range$0.30▼$0.3050-Day Range$0.30▼$0.3052-Week Range$0.25▼$0.30VolumeN/AAverage VolumeN/AMarket Capitalization$20.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Nicox S.A. (OTCMKTS:NICXF) is a French ophthalmic biotechnology company headquartered in Sophia Antipolis. Founded in 1996, the company develops therapies for eye diseases using its proprietary nitric oxide–donating research platform, with a focus on conditions such as glaucoma, ocular surface disease and allergic conjunctivitis. Nicox’s development portfolio has included NCX 470, an investigational nitric oxide–donating prostaglandin analogue being studied for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. The company has also developed other ophthalmic candidates designed to address unmet needs in eye care, including therapies aimed at corneal and retinal disorders. Nicox has commercialized products through licensing and development partnerships rather than relying solely on its own sales infrastructure. Its technologies have contributed to VYZULTA, a glaucoma treatment marketed by Bausch + Lomb, and ZERVIATE, an ophthalmic antihistamine for allergic conjunctivitis marketed in the United States. The company’s activities and partnerships have extended across the United States and international markets.AI Generated. May Contain Errors. Read More Receive NICXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nicox and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NICXF Stock News HeadlinesNICOX SA: Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026September 16, 2026 | finanznachrichten.deNicox to Present Phase 3 NCX 470 Glaucoma Data at AAOpt 2026September 16, 2026 | tipranks.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.October 2 at 1:00 AM | Stansberry Research (Ad)Nicox Extends Cash Runway as NCX 470 Nears Key Regulatory MilestonesSeptember 2, 2026 | tipranks.comNicox Announces Extension of Cash RunwaySeptember 2, 2026 | markets.businessinsider.comNicox Announces April 2027 PDUFA Date for NCX 470 in GlaucomaAugust 27, 2026 | markets.businessinsider.comNicox Gets 2027 FDA Decision Date for Glaucoma Drug NCX 470August 27, 2026 | tipranks.comNicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone PaymentJuly 1, 2026 | markets.businessinsider.comSee More Headlines NICXF Stock Analysis - Frequently Asked Questions How have NICXF shares performed this year? Nicox's stock was trading at $0.30 at the beginning of 2026. Since then, NICXF stock has increased by 0.0% and is now trading at $0.30. How do I buy shares of Nicox? Shares of NICXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:NICXF Previous SymbolNASDAQ:NICXF CIKN/A Webwww.nicox.com Phone(349) 724-5300Fax33-4-97-24-53-99Employees28Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$3.59 million Price / Sales5.76 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book6.00Miscellaneous Outstanding Shares68,920,000Free FloatN/AMarket Cap$20.68 million OptionableNot Optionable Beta0.03 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:NICXF) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nicox SA Please log in to your account or sign up in order to add this asset to your watchlist. Share Nicox With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
